Dataset opportunity
Mimetas — 医疗影像数据集机会
Mimetas 持有的海量医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
48
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
65%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球芯片器官市场在 2024 年的估值为 1.47 亿美元，预计从 2025 年至 2034 年的复合年增长率为 29.7%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
大型
Freshness
实时
Rarity
中等
Accessibility
受限
Legal
公司所有 — 可授权 · 个人身份信息/受监管
Buyer persona
医疗人工智能与诊断影像公司
Mimetas 持有一个独特的医疗影像数据集，该数据集源自其专有的 OrganoPlate® 平台，该平台支持高通量 3D 细胞培养。数据包括来自体外类器官的高分辨率3D 成像和生物测定结果，提供了组织形态、细胞活力和蛋白质定位的详细视图。这个高度特定且结构化的数据集非常适合训练和验证旨在预测人类相关背景下药物毒性和疗效的诊断人工智能模型，这些模型在临床试验之前使用。
该数据集的价值直接与快速扩张的芯片器官市场挂钩，该市场在 2024 年的估值为 1.47 亿美元，预计将以惊人的 29.7% 的复合年增长率增长，到 2034 年将达到 21 亿美元。虽然由于数据的技术性极强、与合作伙伴可能存在的知识产权重叠以及其独特的专有格式，访问权限很复杂，但其稀有性及其在此高增长领域的直接适用性使其成为开发下一代预测健康技术的宝贵资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据技术性极强（生物测定和 3D 成像）；与制药合作伙伴在联合开发项目中可能存在知识产权重叠；专有的 OrganoPlate 硬件创建了独特的数据格式/标准 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
证据证实 Mimetas 拥有源自其专有数据集的3D 组织模型图像，这些图像用于化合物安全性和药代动力学的临床前分析。这些独特的图像对于训练下一代诊断人工智能至关重要，并在快速增长的芯片器官市场中提供了显著的竞争优势，该市场预计将以近 30% 的复合年增长率扩张。对于医疗人工智能公司而言，该数据集代表了开发加速药物发现并减少对传统测试依赖的预测模型的直接途径。
See dimension details ↓- Right to License92
所有权=公司所有，许可=干净
Whether the company can legally license the data out — based on ownership and licensing complexity. - Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
专有领域数据（开放会降低稀有度）
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume70
6 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求极高，这得益于市场对更具预测性、更贴近人类的模型的需求日益迫切，该市场正以 29.7% 的复合年增长率增长，并且由于监管部门放弃动物测试而加速增长。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility44
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength89
5 种证据类型，6 个命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据需求信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit67
⚠ 审查 — Mimetas 的核心业务是销售芯片器官产品及相关的合同研究服务，包括人工智能驱动的分析，使其成为智能的销售者，而不是休眠数据的持有者。问题：公司核心业务是销售产品（OrganoPlate）和合同研究服务（OrganoServices、Custom Services），其中包括生成和分析；该公司明确提供“人工智能和机器学习驱动的分析”，以提供对复杂数据集的“清晰、可操作的答案”，作为其价值主张的一部分；Mimetas 最近被大型分析仪器公司 Bruker 收购，以将其人类模型与 Bruker 的数据分析技术相结合，进一步加强了其地位；该公司的商业模式是为制药公司提供“可操作的数据”和“深入的疾病见解”，这是一种销售智能的形式。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
Mimetas 提供详细的协议文档和元数据，确保任何获取的影像数据都得到充分的背景说明，并适合在高通量筛选结果上训练强大的 AI。
Public datasets
该公司从其实验中生成分析数据集，提供结构化的表格数据，非常适合开发补充性机器学习模型的公司。
Image collection
核心资产是来自复杂3D 组织模型的专有图像集合，提供了训练先进诊断人工智能在细胞和组织层面相互作用所需的丰富、多重数据。
IoT / sensor data
该数据集包括来自专有 OrganoTEER® 平台的实时传感器数据，支持创建预测性时间序列模型，将物理测量与视觉结果相关联。
Medical records / imaging
这些证据指向了一系列用于生成人类相关见解的临床前图像，直接支持专注于预测药代动力学和化合物安全性的人工智能模型。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Mimetas Medical Imaging — a Large medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global Organ-on-a-Chip market was valued at $147 Million in 2024, projected to grow at a CAGR of 29.7% from 2025–2034 (source: GMI Insights).. Investment score 48.0/100 (confidence 0.65). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Renewableconnections — 工业传感器数据集机会
View opportunity →工业Muirhallenergy — 地理空间数据集机会
View opportunity →其他Ensoenergy — 传感器遥测数据集机会
View opportunity →